Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Edwards Lifesciences Corp (NYSE: EW) closed at $83.28 in the last session, down -1.23% from day before closing price of $84.32. In other words, the price has decreased by -$1.23 from its previous closing price. On the day, 2.41 million shares were traded. EW stock price reached its highest trading level at $85.185 during the session, while it also had its lowest trading level at $83.08.
Ratios:
We take a closer look at EW’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 60.09. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 4.00. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Jefferies Upgraded its Hold to Buy on October 29, 2025, while the target price for the stock was maintained at $98.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 09 ’25 when Ullem Scott B. sold 7,700 shares for $84.47 per share. The transaction valued at 650,412 led to the insider holds 39,898 shares of the business.
Markowitz Wayne sold 583 shares of EW for $50,144 on Dec 08 ’25. The CVP, JAPAC now owns 17,563 shares after completing the transaction at $86.01 per share. On Dec 08 ’25, another insider, Markowitz Wayne, who serves as the Officer of the company, bought 583 shares for $86.01 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 48893689856 and an Enterprise Value of 46935556096. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 35.45, and their Forward P/E ratio for the next fiscal year is 28.91. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.21 while its Price-to-Book (P/B) ratio in mrq is 4.74. Its current Enterprise Value per Revenue stands at 7.977 whereas that against EBITDA is 26.244.
Stock Price History:
The Beta on a monthly basis for EW is 0.96, which has changed by 0.14239264 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, EW has reached a high of $87.89, while it has fallen to a 52-week low of $65.94. The 50-Day Moving Average of the stock is 2.80%, while the 200-Day Moving Average is calculated to be 8.40%.
Shares Statistics:
According to the various share statistics, EW traded on average about 4.53M shares per day over the past 3-months and 3331580 shares per day over the past 10 days. A total of 580.70M shares are outstanding, with a floating share count of 572.41M. Insiders hold about 1.36% of the company’s shares, while institutions hold 87.82% stake in the company. Shares short for EW as of 1763078400 were 9771913 with a Short Ratio of 2.16, compared to 1760486400 on 7787459. Therefore, it implies a Short% of Shares Outstanding of 9771913 and a Short% of Float of 1.9199998999999999.
Earnings Estimates
Current recommendations for the stock of the company come from 27.0 analysts. The consensus estimate for the next quarter is $0.68, with high estimates of $0.72 and low estimates of $0.64.
Analysts are recommending an EPS of between $2.63 and $2.41 for the fiscal current year, implying an average EPS of $2.58. EPS for the following year is $2.87, with 32.0 analysts recommending between $3.12 and $2.65.
Revenue Estimates
According to 27 analysts,. The current quarter’s revenue is expected to be $1.54B. It ranges from a high estimate of $1.58B to a low estimate of $1.5B. As of. The current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.39BFor the next quarter, 27 analysts are estimating revenue of $1.57B. There is a high estimate of $1.62B for the next quarter, whereas the lowest estimate is $1.54B.
A total of 32 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $6.07B, while the lowest revenue estimate was $5.89B, resulting in an average revenue estimate of $6.03B. In the same quarter a year ago, actual revenue was $5.44BBased on 32 analysts’ estimates, the company’s revenue will be $6.62B in the next fiscal year. The high estimate is $6.77B and the low estimate is $6.39B.
